Pharmacotherapy for depression during pregnancy has always been a matter of weighing the fetal risks of medication use against the maternal risks of untreated mental illness. In the case of selective serotonin reuptake inhibitors (SSRIs), recent government rulings and research results, including a well-publicized 2007 study in the New England Journal of Medicine, do not always agree about the risk/benefit profile.